Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics


Gracell Biotechnologies Inc. (GRCL): $13.60

0.81 (+6.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GRCL to Watchlist
Sign Up

Industry: Beverages


Ranked

of 38

in industry

GRCL Stock Price Chart Interactive Chart >

Price chart for GRCL

GRCL Price/Volume Stats

Current price $13.60 52-week high $33.70
Prev. close $12.79 52-week low $9.75
Day low $12.56 Volume 46,300
Day high $14.04 Avg. volume 122,297
50-day MA $11.66 Dividend yield N/A
200-day MA $0.00 Market Cap 914.52M

Gracell Biotechnologies Inc. (GRCL) Company Bio


Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.


GRCL Latest News Stream


Event/Time News Detail
Loading, please wait...

GRCL Latest Social Stream


Loading social stream, please wait...

View Full GRCL Social Stream

Latest GRCL News From Around the Web

Below are the latest news stories about Gracell Biotechnologies Inc that investors may wish to consider to help them evaluate GRCL as an investment opportunity.

Gracell Biotechnologies to Participate in Upcoming Virtual Investor Conferences in September

SUZHOU, China and PALO ALTO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences: Citi 16th Annual BioPharma Conference One-on-one and small group meetings: September 8 - 10, 2021 Panel - Exploring

Yahoo | August 26, 2021

Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate Update

SUZHOU, China and PALO ALTO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported its unaudited financial results for the second quarter of the year and recent business highlights. Gracell will host a conference call today, Tuesday, August 17, at 8:00 am Eastern Time. “W

Yahoo | August 17, 2021

Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors

Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced an exclusive license agreement with FutureGen Biopharm ("FutureGen"), an innovative biopharmaceutical company, to develop engineered immune cell therapies targeting Claudin 18.2 ("CLDN18.2") in solid tumors.

Yahoo | August 16, 2021

Gracell Biotechnologies to Report Second Quarter Financial Results on Tuesday, August 17, 2021

SUZHOU, China and PALO ALTO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will release financial results for the second quarter ended June 30, 2021, prior to the open of the U.S. financial markets on Tuesday, August 17. Gracell’s management team will host a correspondin

Yahoo | August 3, 2021

Gracell Biotechnologies to Participate in Fireside Chat at the BTIG Virtual Biotechnology Conference

SUZHOU, China and PALO ALTO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the BTIG Virtual Biotechnology Conference 2021 (details below). BTIG Virtual Biotechnology Conference 2021 One-on-one and small group meetings: August 9-10, 202

Yahoo | July 26, 2021

Read More 'GRCL' Stories Here

GRCL Price Returns

1-mo 34.12%
3-mo 3.42%
6-mo -11.69%
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7121 seconds.